Viking Therapeutics Inc (1VT F) stock market data APIs
€26.1032
-1.3(-5%)
as of May 13, 2025
Try our APIs with
free plan!
Viking Therapeutics Inc Financial Data Overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Prev. Close
26.1032
Open
24.8044
High
26.1032
Low
24.8044
52 wk Range
16.4-83.5
Market Cap
2 872 M
Shares Outstanding
112 M
Beta
0.746
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viking Therapeutics Inc data using free add-ons & libraries
Get Viking Therapeutics Inc Fundamental Data
Viking Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-23
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viking Therapeutics Inc News
New
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025
Viking Therapeutics has experienced a share price increase of 20% over the last month. This comes amidst the company's report of increased financial losses, with a net loss of $46 million in Q1 2025, ...
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025
Viking Therapeutics reported a quarterly net loss of $45.63 million for Q1 2025, up from $27.36 million in the previous year, pushing the stock up 7.7% over the last week. Despite the larger loss, bro...
Q1 2025 Viking Therapeutics Inc Earnings Call
Participants Stephanie Diaz; Manager of Investor Relations; Viking Therapeutics Inc Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc Greg Zante; Chief Financial Off...
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
Viking Therapeutics VKTX reported a first-quarter 2025 loss of 41 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents. The company had incurred a loss of 26 cents in the yea...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
